A bioequivalence study of two telmisartan 80 mg tablets in healthy Indonesian subjects: an open label, three-way, three-period, partial replicate crossover study
- 2 October 2020
- journal article
- research article
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 46 (11) , 1747-1752
Abstract
Telmisartan is highly variable drug indicated for treatment of hypertension. This study aimed to compare the bioavailability of two 80 mg telmisartan tablets in healthy Indonesian subjects. A randomized, open-label, single-dose, three-sequence, three-way, reference-formulation-replicated crossover study was conducted under fasting period with two-week washout period. In this study, thirty-one Indonesian subjects were enrolled and twenty-eight subjects were completed the study. Serial blood samples were collected up to 72 hours following drug administration. Plasma concentrations of telmisartan were determined using high performance liquid chromatography method with fluorescence detector. The pharmacokinetic parameters of AUC0-t, AUC0-∞, and Cmax were assessed for bioequivalence. Bioequivalence acceptance was based on predefined criteria of 90% confidence interval of 80.00-125.00% for AUC parameters and reference-scaled-average bioequivalence of 71.73-139.42% for Cmax. The 90% confidence interval for AUC0-t, AUC0-∞, and Cmax were 96.11%-107.25%, 93.06%-104.36%, and 94.23%-127.01%, respectively. These results indicated that the two formulations of telmisartan were bioequivalent.Keywords
Funding Information
- P.T. Novell Pharmaceutical Laboratories, Jakarta, Indonesia
This publication has 11 references indexed in Scilit:
- Pharmacokinetic and bioequivalence study of a telmisartan/S-amlodipine fixed-dose combination (CKD-828) formulation and coadministered telmisartan and S-amlodipine in healthy subjectsDrug Design, Development and Therapy, 2018
- Comparative pharmacokinetics of a fixed-dose combination vs concomitant administration of telmisartan and S-amlodipine in healthy adult volunteersDrug Design, Development and Therapy, 2017
- Pharmacokinetics of a telmisartan/rosuvastatin fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjectsInt. Journal of Clinical Pharmacology and Therapeutics, 2015
- Telmisartan2015
- Bioavailability and bioequivalence in drug developmentWIREs Computational Statistics, 2014
- Telmisartan: a review of its pharmacodynamic and pharmacokinetic propertiesExpert Opinion on Drug Metabolism & Toxicology, 2010
- Rapid determination of telmisartan in human plasma by HPLC using a monolithic column with fluorescence detection and its application to a bioequivalence studyJournal of Chromatography B, 2009
- Evaluation of a Scaling Approach for the Bioequivalence of Highly Variable DrugsThe AAPS Journal, 2008
- Comparative Effects of Telmisartan in the Treatment of HypertensionThe Journal of Clinical Hypertension, 2002
- Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertensionJournal of Human Hypertension, 2000